All posts by medical

BodyViz Launches International Reseller Program to Assist Universities in Moving Anatomy Labs Online – Southernminn.com

April 24, 2020 medical

BodyViz unveils strategy to deliver online virtual dissection for anatomy programs in higher education and medical institutions across the world

CLIVE, Iowa, April 21, 2020 /PRNewswire/ -- BodyViz, a leader in 3D anatomy learning technology, has launched an all-new international reseller program aiming to bring its cutting-edge 3D virtual dissection platform to higher education and medical institutions throughout the world. Institutions often face limited access to cadaveric specimens, making it difficult for them to provide their students with accurate and detailed anatomical content. In light of COVID-19, this challenge has increased exponentially as institutions continue to transition into online/remote learning. BodyViz intends to tackle these issues by providing hands-on virtual dissection experiences for students in both traditional and online learning environments, using 3D visualizations created directly from real human and animal anatomy.

"We chose to work with BodyViz because of the flexibility and scalability of their 3D Anatomy Learning Platform. Having the ability to augment anatomy education with virtual anatomy labs all across our country in any settingtruly opens the door to significantly enhancing the learning environment and creates more opportunities for our company," said Vipin Chopra, CloudNCare, Managing Director.

With its newly developed online anatomy lab and all-new software release in 2020, BodyViz provides unlimited access to active learning resources for students both inside and outside of the traditional anatomy lab and classroom. Students can virtually dissect, examine, and peel away tissue layers to explore the complex 3D spatial relationships of interconnected systems. Using BodyViz Interactive Anatomy Content modules, students can test their understanding directly within their institution's preferred learning management system.

"We really focused on refining the user experience for students and instructors in our latest software release. Utilizing the foundation of the BodyViz 3D Anatomy Learning Platform that students and instructors have embraced, we've made the process of integrating virtual resources into anatomy curricula much easier for the instructorand more effective and engaging for the students," said Mike Stuart, BodyViz, Executive Vice President.

The cutting-edge technology and flexibility of BodyViz's 3D Anatomy Learning Platform help anatomy instructors significantly increase their students' interaction and exposure with real anatomical resources using computers, tablets, and applications alike. This is particularly important for international universities today, where access to cadaveric specimens is growing increasingly scarce and expensive. BodyViz tackles this issue by providing institutions with a cost-effective way to engage their students with active learning resources.

Follow the link provided (https://docsend.com/view/s2vn95b) to download the BodyViz Reseller Brochure and get started today.

Contact:Mike StuartExecutive Vice PresidentBodyVizreseller@bodyviz.comwww.bodyviz.com

Read this article:
BodyViz Launches International Reseller Program to Assist Universities in Moving Anatomy Labs Online - Southernminn.com

Anatomy

‘Extraction’ | Anatomy of a Scene – The New York Times

April 24, 2020 medical

Hi. My name is Sam Hargrave, director of Extraction. So at this point, were in the middle of what we would term a oner. Its a long continuous shot that we came up with, a way to do that kind of a unique chase scene. And were escaping with Chris Hemsworth, who plays Tyler Rake, and Rudhraksh Jaiswal who plays that Ovi. Alright, kid, you trust me? No. Good. This jump and at that moment, we had a stitch. So we could infuse our actors into the action and then use the doubles for the dangerous part. And for that jump, I was actually on a wire leaping behind our stunt doubles. And coming down those stairs, thats me running backwards with a camera, trying to keep our actors in frame, keep up with their speed, not fall on my butt. We work our way through this whole series of hallways. And when we enter this room, we actually, on that door kick, we moved to another location. So thats a different day of shooting, different time. Stay on my shoulder, all right? And this fight here, weve got Randeep Hooda and Chris Hemsworth going at it. They spent weeks rehearsing together. Because the beauty of this is it looks sloppy. It looks like theyre struggling for their lives. And it looks messy. But that comes from hours of rehearsal so they could put the acting into this. So again, here, we build in a hidden cut where we can put the doubles in. And as you see, the camera goes down with them. Again, thats me on a wire, jumping over a balcony, and gliding down with them. And for that, we kind of set that all up. We built the balcony. It didnt exist. We parked the truck in the right place. And the stunt team rehearsed and rehearsed and rehearsed to get the timing of that right and the distancing. And it was really challenging to kind of keep both actors in frame for that fall just because the nature of the jump. I mean, Im on a wire, trying to jump with a camera, keep them in frame. And then when we land in the streets, what we thought would be really fun was to have the actors interacting with the environment, the vehicles passing by. This is just a day in the life of for these people. But these guys are locked in a life and death struggle with knives. And yet, life goes on. You know, this is busy street. People are watching like theyve gone to the cinema. And you know, again, this hours of rehearsal with these two actors so that we could have the intensity that we needed. And then a little shock value here. [GRUNTING] [CAR SCREECHES] The thing that was interesting about this moment is, and what we tried to do to make kind of a unique perspective, was do what people arent expecting, which you take out your hero. Just take him out of the fight. And then focus on the bad guy. And we just thought it was fun, a different way to kind of follow action was to leave your hero out of it. So youre thinking, wait, what happened to Rake? Is he going to come back? And you know, leave people wanting more.

Read this article:
'Extraction' | Anatomy of a Scene - The New York Times

Anatomy

Ibn al Nafis: The discovery of human blood circulation in the 13th Century – TRT World

April 24, 2020 medical

Ibn al Nafis figured out pulmonary microcirculation 300 years before William Harvey, who claimed to be the first scientist to do so, was born.

Ibn al Nafis (Ala ad-Din Abu al Hasan Ali Ibn Abi-Hazm al Qarsh) was a Muslim polymath known as the father of Circulatory Physiology. He is considered to be the first to describe the pulmonary circulation of the blood, although the Western educational institutes attribute that discovery to the 17th-century English scientist William Harvey.

Ibn al Nafis was a versatile thinker, making immense contributions to various fields such as politics, anatomical studies and jurisprudence. Despite his fame in ophthalmology, and performing several human dissections, his extensive work on pulmonary circulation stands out in the field of science.

The 13th-century thinker also gave an early insight into the coronary and capillary circulations.

The early studies on heart and anatomy of circulation first started in 500 BC with observations of Alcmaeon of Croton about the arteries and veins in animal dissections. His studies were confirmed by Herophilus of Chalcedon in 300 BC during cadaver studies. Then, Aristotle described the heart as a three-chambered organ in 350 BC.

Before Ibn al Nafis, Greek Physician Galen claimed that there was no passage in the septum and believed that the circulation system originated from the liver. He also though that although blood passed through invisible pores in the interventricular septum from right to left, venous and arterial systems were two separate closed systems, the theory which had existed since the 2nd Century AD.

Ibn al Nafis was the first to contradict Galen's theory by describing the flow of blood between heart and lungs correctly. He also described the interventricular septum as a non-porous wall that is impermeable to blood. Therefore, Ibn al Nafis adopted the concept of pulmonary circulation as the only way for blood to pass between the two sides of the heart.

As a devout Muslim and physician, he contributed visibly much to the body of knowledge in anatomy and medicine. Hence, today scholars are able to find the first description of coronary vessels and the correct definition of the blood supply of the heart likewise the correct description of the pulmonary circulation.

All his discoveries spread across the world and were translated into Latin by Andreas Alpagus and appeared in the works of various European scholars from Servetus to Harvey.

Ibn al Nafis wrote many books in medicine but Sharah al Tashreeh al Qanoon (Commentary on the anatomy of the Canon of Avicenna) has been the most famous amongst his works.

The book was forgotten until the time when Egyptian physicians discovered a manuscript with the title Commentary on the anatomy of the Canon of Avicenna in the Prussian state library in Berlin, Germany, in 1924.

Commentary on the anatomy of the Canon of Avicenna (Ibn Sina) contains the first description of the pulmonary circulation by explaining:

The OriginsAla ad-Din Abu al Hasan Ali Ibn Abi-Hazm al Qarshi, known as Ibn Nafis Damishqi, was born in a small town near Damascus called Qarsh in 1210.

In his early life, he studied theology, philosophy and literature. When he turned 16, he started studying medicine, which lasted 10 years at the hospital in Damascus, founded by the Turkish prince Nureddin Mahmud Zengi in the 12th Century.

In 1236, Ibn al Nafis and his colleagues moved to Egypt following the request of the Ayyubid sultan al Kamil. He first appeared as the chief physician at al Naseri hospital which was founded by Saladin the victor where he practised medicine for several years.

He mostly spent his life in Egypt and witnessed massive incidents like the fall of Baghdad and the rise of Mamluks. He became the personal physician of many leaders such as Sultan Baibars.

At the age of 74, Ibn al Nafis became the chief physician of the newly founded al Mansori hospital where he worked there until the end of his life. He died in Cairo following. Prior to his death, Ibn al Nafis donated his entire library and house to Qalawun Hospital.

Source: TRT World

See the article here:
Ibn al Nafis: The discovery of human blood circulation in the 13th Century - TRT World

Anatomy

Despite Shortened TV Season, Which of Your Storyline Wishes Still Came True? – TVLine

April 24, 2020 medical

Grey’s Anatomy: 10 People Callie Should Have Ended Up With (Other Than Arizona) – Screen Rant

April 24, 2020 medical

If there was one character onGrey's Anatomy who had the worst luck with love, it was Callie Torres. Two of her marriages ended up in divorce after both her spouses cheated on her, and the father of her child died as the result of the injuries he sustained in a plane crash.

RELATED:Grey's Anatomy: Why Richard & Bailey Aren't Real Friends

To top it all off, Callie found out that her ex-girlfriend also contributed to the death of her friend. While the writers hinted at a possible reunion between Callie and Arizona in the season 14 finale, some fans believe the reunion won't work because there is too much history between them. So who should Callie have ended up with? From Hahn to Owen, here are 10 people Callie should have ended up with instead.

Heather (otherwise known as Heather steak knives) was the first person Callie dated after her split with Arizona. Although the date was cut short, the two seemed to have had a good time, with the pair sharing a kiss after Callie was returned to the hospital.

However, this romance was cut short when Arizona scared Callie off after revealing Heather was one of her crazy exes. While it looks like Arizona was being nice by warning Callie, some have also wondered if she was sabotaging the romance. It would have been interesting to see Heather's side of the story.

In the aftermath of her divorce, Callie also went on a date with was Dan Pruitt. Fans will have to cast their minds back to season 11 if they want to remember Dan. He was a police officer who was admitted to the hospital after he and some colleagues were shot in a bank robbery gone wrong.

RELATED:Grey's Anatomy: 10 Reasons Why Cristina & Callie Aren't Friends

He and Callie seemed to hit it off, with the policeman bold and compassionate attitude gaining her interest. However, after one date, she later admitted that he was "boring." It seemed like it was another wasted opportunity, especially since he seemed like a genuine guy.

Sadie Harris was another potential love interest of Callie's that the writers didn't fully develop. Introduced in season 5, Callie expressed an interest in the surgical intern after the two flirted whenever they met. However, this relationship was cut short when Sadie decided to quit so she could travel the world.

It's a shame considering the writers had an easy way of leading into it with Mark and Lexie's romance. Callie and Sadie could have teamed up to ensure their friends' relationship remained a secret. Sadie could have even come back in season 12 and replaced Penny's character.

If fans were wondering who else Callie could have ended up with, what about Grey-Sloan's very own McDreamy? Some might think it is random, but, in reality, it's not. The pair have quite a lot in common.

RELATED:Grey's Anatomy: Why Alex & Arizona Aren't Real Friends

For instance, they both have strained relationships with their families. They both had Mark Sloan as a best friend, meaning there had to be some interests they shared. Not to mention how extremely loyal they were to their colleagues, even the ones they didn't like. It could have worked...

Although many fans weren't fond of the cardiothoracic surgeon, they can't say that Hahn didn't make Callie happy. In season 4, Callie and Hahn dated for a brief time while the orthopedic surgeon was coming to terms with her sexuality. However, their relationship ended once Hahn found out about the 'Denny Duquette' situation.

While Hahn hasn't been seen since her resignation, it would have been nice for Callie to get closure on the relationship. Instead of moving to New York, maybe Callie could have gotten a job offer from wherever Hahn ended up.

In season 6, fans were completely shocked to find out that Callie and Alex had hooked-up sometime after he assisted on 'Heart in an elevator.' However, this has led fans to wonder what would have happened if Alex and Callie had decided to make things official.

RELATED:Grey's Anatomy: 10 Other Ways Alex Karev Could Have Left The Show

If Alex and Callie became an official couple, it wouldn't have been the worst thing in the world. They were both family-orientated, and they both dreamed of having families of their own. He also proved he could be someone she could rely on, which is something that can't be said for other characters.

Although Callie and Carina have never met, it doesn't stop people from imagining what a power couple they could have been. If Callie had moved to New York with Carina instead of Penny, fans wouldn't have minded. Why? Because fans have gotten to know Carina and seen what a rockstar she is.

Like Callie, she is very outgoing and passionate. Carina is also family-orientated and would go to the ends of the earth to make them happy. If they would have met before Callie went to New York, they would have hit it off.

One of the most underrated friendships on the show had to be Callie and Owen's. In the aftermath of their failed marriages, Owen and Callie grew closer as they attempted to move on. Their relationship continued to grow when they worked on a clinical trial, and Owen testified on behalf of her in Sofia's custody trial.

RELATED:Grey's Anatomy: 10 Facts About Owen Hunt Many Fans Don't Know

Since Owen and Callie had been burnt by love, it would have only been natural for the two to gravitate towards one another. It wouldn't have been surprising either if their relationship took a romantic turn. After all, they do share the same family values.

Another person that could have been a potential love interest for Callie was Addison. As fans know, Callie and Addison were very close friends. Callie was one of the few people who truly knew what happened in her relationship with Mark. Addison was also one of the few people who helped Callie to figure out her sexuality.

Fans wouldn't have minded if the writers decided to put Callie and Addison together since they had such good chemistry. It would have been successful too, since they were both very reliable and loyal people.

Out of all the characters on the show, the best person for Callie was Mark.If there was one person in the entire world who never let Callie down, it was Mark. His unwavering loyalty and support was the one constant thing in her life.

Mark was there for her when she was coming to terms with her sexuality, when George died, and when Arizona left to go to Africa. Mark was also an important factor in her recovery after the car crash. If he hadn't have died, he could have moved to New York with Callie and Sofia and reopened his practice.

NEXT:Grey's Anatomy: 10 Continuity Errors In Grey's Anatomy

NextJames Bond: 5 007 Kills That Went Too Far (& 5 That Were Justified)

A writer, reader and tv fanatic, Kayleigh enjoys reading movie news and your film reviews. She has attained an Undergraduate degree in Creative Writing and is also the creator of the film and television blog 'The Critics' Corner'.

Read the rest here:
Grey's Anatomy: 10 People Callie Should Have Ended Up With (Other Than Arizona) - Screen Rant

Anatomy

Grey’s Anatomy Showrunner Reveals Whether Alex and Izzie Could Return – TV Fanatic

April 24, 2020 medical

Grey's Anatomy may have reunited Alex (Justin Chambers) and Izzie (Katherine Heigl) off-screen, but could they actually stage a return to the series down the line?

The showrunner of the series was asked that question in a recent interview with Deadline following the impromptu sixteenth season finale.

In a wild twist of fate, Alex left Jo behind in Seattle and reunited with his former love Izzie, and they are living on a farm in Kansas, where they are raising their children.

Given that Heigl was not on the best of terms with Grey's creator Shonda Rhimes when she exited the series, many fans thought a return would be out of the question.

But for current showrunner, Krista Vernoff, she thinks it would not be impossible.

"When I left the show in season 7, people asked me if there was any chance of me ever coming back, and I was smart enough to say, 'Never say never'," she told Deadline. "Here I am, so who knows?"

While it seems unlikely to ever happen, at least fans can take solace in the fact that Alex and Izzie got a happy ending.

It wasn't enough for some fans, but it was a way to say goodbye to the characters amid Justin Chambers' exit from the series.

Grey's Anatomy has a track record of killing off beloved characters, so at least Alex and Izzie are still living.

That means the possibility is always there for them to return in some capacity, but given that all signs are pointing towads Grey's Anatomy Season 17 being the last-ever season, it seems unlikely for now.

Grey's Anatomy recently wrapped its 16th season with four episodes unproduced, but the impromptu finale worked well in bringing the show to a close ... for now.

ABC has already ordered up Grey's Anatomy Season 17, but one star has said he is "confident" it will be the show's last hurrah.

Whether that will be the case, we don't know.

What do you think of the potential returns of Alex and Izzie?

Hit the comments below.

Remember you can watch Grey's Anatomy online right here via TV Fanatic.

Edit Delete

Paul Dailly is the Associate Editor for TV Fanatic. Follow him on Twitter.

See the article here:
Grey's Anatomy Showrunner Reveals Whether Alex and Izzie Could Return - TV Fanatic

Anatomy

Grey’s Anatomy boss responds to whether Justin Chambers or Katherine Heigl could return – digitalspy.com

April 24, 2020 medical

Grey's Anatomy season 16 spoilers follow.

Grey's Anatomy showrunner Krista Vernoff has addressed whether or not Justin Chambers or Katherine Heigl could return to the series.

Chambers made his exit from the show during season 16, and in a twist, his character Alex Karev was later revealed to have reunited with Izzie Stevens, who was played by Heigl between 2005 and 2010.

Related: Grey's Anatomy boss confirms major character's fate after surprising diagnosis

Alex and Izzie are now living happily together and raising twins on a farm in Kansas.

In an interview with Deadline, Vernoff was asked about the possibility of Chambers or Heigl reprising their roles in the future, especially since neither of them were killed off. The showrunner replied by saying that a shock return for either character wouldn't be impossible.

"When I left the show in season 7, people asked me if there was any chance of me ever coming back, and I was smart enough to say, 'Never say never'," she said. "Here I am, so who knows?"

During the same interview, Vernoff admitted that she wasn't surprised by the divisive reaction to how Alex was written out.

"I believe that there would've been at least as big an outcry if we had killed that character off-camera, and those were our choices," she said, before adding that she "felt satisfaction" and was "really happy" with Alex's fate.

The 16th season ended four episodes early, resulting in several planned storylines including for Teddy Altman and Andrew DeLuca being cut.

There have also been reports that a major character death was supposed to happen in the original season finale.

Grey's Anatomy airs on Thursdays on ABC in the US. It airs on Sky Witness in the UK with selected episodes also available on NOW TV.

Digital Spy now has a newsletter sign up to get it sent straight to your inbox.

Looking for more TV recommendations and discussion? Head over to our Facebook Group to see new picks every day, and chat with other readers about what they're watching right now.

Read this article:
Grey's Anatomy boss responds to whether Justin Chambers or Katherine Heigl could return - digitalspy.com

Immunology

sup> Virtual Summit on Cancer and Immunology Research 2020 on SelectScience – SelectScience

April 24, 2020 medical

Reserve your place today for the inaugural SelectScience Virtual Summit on Cancer and Immunology Research 2020, which runs from May 11-13, 2020.

As an entirely digital event, this new Summit is designed to ensure that knowledge share, effective communication and collaboration in this critical field is not only continued but flourishes at this challenging time.

Register to attend presentations by world-leading scientists and technology innovators, workshops, video interviews, virtual resource hubs, the latest product and application news, as well as networking and live-chat opportunities.

Why attend?

Headline topics include CAR T-cell therapy, immunotherapy, genetics and CRISPR, the microbiome and cancer, liquid biopsies, drug delivery mechanisms and much more.

Register today to keep up with advances in cancer and immunology research and technologies further details to follow soon

Start communicating: #CancerImmunologySummit

See the original post:
sup> Virtual Summit on Cancer and Immunology Research 2020 on SelectScience - SelectScience

Immunology

Verastem Oncology Appoints John H. Johnson to its Board of Directors – Business Wire

April 24, 2020 medical

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that it has appointed John H. Johnson to its Board of Directors. Mr. Johnsons career covers multiple executive management roles at leading global corporations where he was responsible for overseeing oncology and immunology drug development initiatives and commercialization. Mr. Johnson will serve on the Compensation and Nominating and Governance Committees.

We are pleased to welcome John to the Verastem Oncology Board. His deep background in oncology and immunology at Johnson & Johnson and Eli Lilly will be helpful as the Company advances its new strategic approach to prioritize the clinical development of VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, for the treatment of KRAS mutant solid tumors, said Michael Kauffman, M.D., Ph.D., Lead Director of the Verastem Oncology Board. His seasoned experience as a senior biotechnology executive and breadth of knowledge in the oncology space will provide key insights to further unlock the value of the Companys clinical pipeline.

I am very excited to support Verastem Oncology on their mission to develop targeted therapeutics to treat areas of unmet need in cancer, said Mr. Johnson. I feel that my experience will be beneficial in advancing the Companys pipeline through this next stage of growth and late-stage development. I look forward to collaborating with the Board of Directors and management team on these initiatives.

Mr. Johnson is a recognized leader in the pharmaceutical and biotechnology industry with more than three decades of experience. He served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, responsible for the Biotechnology, Immunology and Oncology commercial businesses. Previously, Mr. Johnson served as president of Eli Lilly & Company's Worldwide Oncology Unit, following the company's 2008 acquisition of ImClone Systems, Inc., where he served as Chief Executive Officer and a member of ImClones Board of Directors. He has served as a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO). Mr. Johnson also served as Chairman, President and Chief Executive Officer of Dendreon Corporation and has held other executive roles within the biotech industry. Currently, he is a member of the Board of Directors of Strongbridge Biopharma plc (SBBP), BioAgilytix (private) and Portola Pharmaceuticals Inc (PTLA).

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and RAF/MEK inhibition.

Our first FDA approved product is available for the treatment of patients with certain types of indolent non-Hodgkins lymphoma (iNHL).

For more information, please visit http://www.verastem.com.

Forward looking statements notice

This press release includes forward-looking statements about Verastem Oncologys strategy, future plans and prospects, including statements related to the opportunity to rapidly advance the development of clinical programs through Verastem Oncologys expanded development pipeline and strengthened balance sheet, the timing of top-line results for clinical trials, anticipated reductions in operating expenses from Verastem Oncologys strategic realignment, the timing of commencing a registration-directed trial for CH5126766 (VS-6766) and financial guidance estimates. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement.

Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks and uncertainties, among other things, regarding: the success in the development and potential commercialization of our product candidates, including defactinib in combination with CH5126766 (VS-6766); the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis or result in unmanageable safety profiles as compared to their levels of efficacy; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the scope, timing, and outcome of any legal proceedings; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of our product candidates; whether preclinical testing of our product candidates and preliminary or interim data from clinical trials will be predictive of the results or success of ongoing or later clinical trials; that the timing, scope and rate of reimbursement for our product candidates is uncertain; that third-party payors (including government agencies) may not reimburse; that there may be competitive developments affecting our product candidates; that data may not be available when expected; that enrollment of clinical trials may take longer than expected; that our product candidates will experience manufacturing or supply interruptions or failures; that we will be unable to successfully initiate or complete the clinical development and eventual commercialization of our product candidates; that the development and commercialization of our product candidates will take longer or cost more than planned; that we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the CH5126766 (VS-6766) license agreement; that we may not have sufficient cash to fund our contemplated operations; that we may be unable to make additional draws under our debt facility or obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity, debt financing or otherwise; that we will be unable to execute on our partnering strategies for defactinib in combination with CH5126766 (VS-6766); that we will not pursue or submit regulatory filings for our product candidates, and that our product candidates will not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients.

Other risks and uncertainties include those identified under the heading Risk Factors in the Companys Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) on March 11, 2020 and in any subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Verastem Oncologys views as of the date hereof, and the Company does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Read the original here:
Verastem Oncology Appoints John H. Johnson to its Board of Directors - Business Wire

Immunology

Johnson Earns Alumni Association Teaching Award – UMM News, Sports & Events

April 24, 2020 medical

University of Minnesota Morris Assistant Professor of Biology Rachel Johnson has earned the 2020 UMN Morris Alumni Association Teaching Award. Johnson stands out among peers for her commitment to undergraduate teaching and learning. An immunologist, Johnson is a particularly appropriate choice this year.

"Given our current state of affairs, it is hard to overestimate the impact Dr. Johnson's course development on vaccines, epidemics and now pandemics has had," nominators write. "The particularly wonderful aspect of these courses is that they are for all our liberal arts studentsnot just science students. The need could not be greater, given Dr. Johnson's emphasis on critical thinking and communication skills development."

"Rachel has made extraordinary contributions to her students and the campus, providing an exemplary model of liberal arts learning both within and well beyond the study of biology," adds Vice Chancellor for Academic Affairs and Dean Janet Schrunk Ericksen.

Johnson is an assistant professor of biology and a member of the Masonic Cancer Center. She holds a PhD in immunology from the Mayo Graduate School and a BA in biochemistry and molecular biology from Boston University. Her areas of expertise include immunology, cancer biology, and molecular biology.

The University of Minnesota Morris Alumni Association established the UMMAA Teaching Award in 1997 to honor individual faculty members for outstanding contributions to undergraduate education. Learn more at alumni.morris.umn.edu

See original here:
Johnson Earns Alumni Association Teaching Award - UMM News, Sports & Events